Abstract: The present invention relates to the use of compounds in the treatment of a viral infection, wherein the virus is selected from the Orthomyxoviridae family or wherein the virus is West Nile virus.

Abstract: This invention provides a novel protein. Experimental results have shown that the protein has agonist activity at three receptors, namely the glucagon-like peptide 1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (Gcg) receptor, and has both blood glucose lowering and body weight reducing functions.

Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Abstract: Described are processes for the manufacture of compounds containing a (S)-4,5-dihydro-1H-pyrazole ring. These processes include a chiral resolution step of an intermediate using selected chiral resolving agents. For example, the chiral resolving agents may be selected from (?)-quinine, (R)-phenethylamine, (S)-phenethylamine, (S)-1-naphthylethylamine, (R)-(?)-2-amino-3-methyl-1-butanol, (?)-cinchonidine, (?)-spartein, (R)-1-naphthylethylamine, D-arginine, L-lysine, (S)-(+)-2-pyrrolidinemethanol and (1R,2S)-(+)-cis-1-amino-2-indanol.

Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Abstract: An organic electroluminescent material and a method preparing the same are disclosed. Material of the organic electroluminescent includes diboranthracene fluoride which has R1 group and R2 group. Material of the organic electroluminescent has a low single-triplet energy gap. Moreover, the preparation method and synthesis pathway are simple, with stable performance, thereby effectively reducing preparation costs of the organic electroluminescent material in display panels, and improving the luminescence performance of the panels.

Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.

Abstract: In one aspect, the invention relates to a process for preparing a compound of formula (XII), wherein PG is a protecting group, or a compound of formula (XI), comprising the steps of: (i) treating a compound of formula XIII, wherein PG is a protecting group, with N-methylpiperazine to form a compound of formula XII, wherein said compound of formula XII is in the form of a mixture of cis and trans isomers; (ii) combining the mixture formed in step (i) with an organic solvent and heating the solvent mixture so formed; (iii) isolating the trans-isomer of the compound of formula XII from the solvent mixture formed in step (ii); and (iv) optionally treating said trans-isomer of the compound of formula XII with an acid to form a compound of formula XI; and isolating said compound of formula XI. Further aspects of the invention relate to processes for preparing pyrimido-diazepinone derivatives using the above process and intermediates.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, comprising a 2-(4-(1-hydroxypropane-2-yl)phenyl) isoindoline-1-one compound or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition for preventing or treating Parkinson's disease can increase the protein level of PGC-la in the brain of an individual by successfully passing through the blood-brain barrier (BBB).

Abstract: A process for purifying a liquid feedstock comprising a monoclonal antibody and impurities, the process comprising passing the liquid feedstock through an apparatus comprising at least two processing units, each such unit producing a product stream containing purified monoclonal antibody and optionally a waste stream comprising at least some of the impurities, wherein each unit comprises specified components (i) to (v) which include a multiple inlet flow-controller comprising two or more variable flow inlet valves for in situ production of a bioprocessing liquid by combining at least two liquids in a desired ratio. One of the units performs chromatography and another performs viral inactivation. The units may be essentially the same except for a device they contain, leading to advantages in terms of simplicity, cost and ease of operation, lower risk of operator error, easier maintenance and lower inventory of spare parts.

Abstract: The present disclosure provides methods, uses, and pharmaceutical compositions with utility in the treatment of acute lung injuries or chronic lung diseases including, bronchopulmonary dysplasia and exacerbations of bronchopulmonary dysplasia.

Abstract: In one aspect, the technology relates to a method of producing Ac, the method including preparing a phosphate-modified titania material to produce an ion-exchange material, contacting a solution including 229Th with the ion-exchange material to produce a Th-loaded titania material, eluting the Th-loaded titania material with a wash solution to produce an eluted solution containing eluted compounds including 225Ac, concentrating the eluted solution to generate eluted compounds including the 225Ac, and separating the 225Ac from the eluted compounds.

Abstract: Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.

Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a ?5-containing GABAA receptor agonist (e.g.

Abstract: Disclosed are a kind of fused ring derivatives, and specifically disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

Abstract: Certain embodiments described herein include methods and formulations for treating or preventing symptoms and conditions associated with sepsis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

Abstract: A personal care composition comprising a surfactant-insoluble piroctone complex and a surfactant.

Abstract: The present disclosure is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In certain embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, Fc?RI, FcRN, Transferrin or Macrophage Scavenger receptor.

Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.